These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36389687)

  • 1. Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.
    Wurster S; Watowich SS; Kontoyiannis DP
    Front Immunol; 2022; 13():1018202. PubMed ID: 36389687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis.
    Wurster S; Albert ND; Bharadwaj U; Kasembeli MM; Tarrand JJ; Daver N; Kontoyiannis DP
    Front Immunol; 2022; 13():838344. PubMed ID: 35251033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
    Song Y; Fu Y; Xie Q; Zhu B; Wang J; Zhang B
    Front Immunol; 2020; 11():1956. PubMed ID: 32983126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
    Kawashima S; Togashi Y
    Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
    Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
    Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
    Wang Y; Zhang H; Liu C; Wang Z; Wu W; Zhang N; Zhang L; Hu J; Luo P; Zhang J; Liu Z; Peng Y; Liu Z; Tang L; Cheng Q
    J Hematol Oncol; 2022 Aug; 15(1):111. PubMed ID: 35978433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
    Melaiu O; Lucarini V; Giovannoni R; Fruci D; Gemignani F
    Semin Cancer Biol; 2022 Feb; 79():18-43. PubMed ID: 32659257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candida auris Bloodstream Infection Induces Upregulation of the PD-1/PD-L1 Immune Checkpoint Pathway in an Immunocompetent Mouse Model.
    Wurster S; Albert ND; Kontoyiannis DP
    mSphere; 2022 Apr; 7(2):e0081721. PubMed ID: 35224979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance.
    Weng CY; Kao CX; Chang TS; Huang YH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33514004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell-intrinsic SETD2 inactivation sensitizes cancer cells to immune checkpoint blockade through the NR2F1-STAT1 pathway.
    Zheng X; Luo Y; Xiong Y; Liu X; Zeng C; Lu X; Wang X; Cheng Y; Wang S; Lan H; Wang K; Weng Z; Bi W; Gan X; Jia X; Wang L; Wang Y
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nascent Nanoformulations as an Insight into the Limitations of the Conventional Systemic Antifungal Therapies.
    Kaur M; Shivgotra R; Bhardwaj N; Saini S; Thakur S; Jain SK
    Curr Drug Targets; 2023; 24(2):171-190. PubMed ID: 36443967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
    Mei Z; Huang J; Qiao B; Lam AK
    Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to immune checkpoint inhibitors.
    Nagasaki J; Ishino T; Togashi Y
    Cancer Sci; 2022 Oct; 113(10):3303-3312. PubMed ID: 35848888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy.
    Lee J; Han Y; Wang W; Jo H; Kim H; Kim S; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
    Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
    Wang Z; Wang Y; Gao P; Ding J
    Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.